Natco Pharma Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i773geuy1q4q6iwc92ip4szj.pdf

Key Takeaways


Agro Division: The New Growth Engine

Rajeev Nannapaneni: "When we enter a market we don't try to be the -- we always like the only show in town or the only 1 or 2 shows in town so that your chances of success are much higher compared to a..."

Revlimid: The Known Unknown


Base Business Transformation

Rajeev Nannapaneni: "I'm exactly doing the opposite of what the industry is doing. So we are making money in US, when nobody is making money in the US and people are making money in India, we're not making as much money as in India."

Domestic Business: The Long Fix

Rajeev Nannapaneni: "Doing no deal is better than doing a bad deal, right? So I think we'll find something. I'm confident. You have to be patient. You have to wait. Sometimes -- see, I am not under pressure in that sense, right, because we have steady earnings"

Earnings Pattern & Lumpiness


Guidance & Commitments

CommitmentSpecificsTimeline
Agro revenueINR 150–200 crNext 12 months
Agro net margin20–25% after all expensesOngoing
Full-year FY23 top lineINR 2,700–2,800 crFY23
Full-year FY23 PATCloser to INR 700 crFY23
Revlimid volume shareMove from mid-single-digit to double digitsFrom March 7 onwards
Revlimid profit share bookingRecognised in Q4 FY23 and Q1 FY24Q4 FY23, Q1 FY24
Brazil subsidiary launches5–6 launchesNext 12 months
Domestic M&A dealHopeful of consummating a deal2023
Domestic business share targetGrow to 30–35% of top line5–7 year cycle
Agro business long-term scaleGrow to INR 400–500 crNo fixed date; exports eventually
Karnataka agro sales teamFull team in placeNext 1–2 months
US new filings FTF clarityClarity on first-to-file statusNext 2–3 months

Key Metrics

MetricQ3 FY23
Consolidated total revenue₹513.3 cr, versus ₹590.7 cr in Q3 FY22 which included a one-time licensing fee
Consolidated net profit₹62.3 cr, versus ₹80.4 cr in Q3 FY22
Full-year FY23 revenue guidance₹2,700 cr to ₹2,800 cr, expected highest in company history
Full-year FY23 PAT guidanceCloser to ₹700 cr, expected highest in company history
Agro division revenueLess than ₹10 cr, initial quarter post-launch
Agro division revenue expectation (next 12 months)₹150 cr to ₹200 cr
Agro division long-term revenue expectation₹400 cr to ₹500 cr, mostly branded India business with eventual export pickup
Agro division expected net margin20% to 25%, broadly ₹25 to ₹30 on ₹100 after all expenses
Domestic formulation revenue~₹400 cr, approximately 15% to 16% of top line
Cash on books₹1,030 cr, with very little debt except working capital debt
Subsidiary revenue₹169 cr for the quarter
Subsidiary PAT contributionNearly 40% of consolidated PAT
US commercial products~26 commercial products, of which 11 are Para IV approved
Para IV pipeline19 Para IV filings in pipeline as of March 31, 2022
CTPR market size~₹3,000 cr